Skip to main content

BHC Invests in 20/20 GeneSystems to Bring Lung Cancer Test to China

NEW YORK (GenomeWeb) – BHC Center of Financial and Investment Business today announced it has invested in 20/20 GeneSystems to help bring the company's diagnostic test for lung cancer to China.

BHC, an Atlanta-based affiliate of Bao Hao Investment Management of Shanghai, said that the equity investment is the first of what it expects to be several in 20/20 GeneSystems. BHC did not disclose the amount of the investment.

20/20 GeneSystems' test, called PAULA's test — short for Protein Assay Using Lung Cancer Analytes — measures a panel of biomarkers that result from the early presence of a tumor and is marketed in the US by the Genesys BioLabs business unit of 20/20 GeneSystems.

BHC and 20/20 GeneSystems noted that China has a particularly high rate of smokers, as more than half of all men in the country smoke, according to the World Health Organization. That along with air pollution in urban areas has resulted in a high incidence of lung cancer in the country.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.